Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roflumilast in Type 2 Diabetic Patients With Diabetic Neuropathy
NCT05369793Phase 3Completed
- Sponsor
- Tanta University
- Start
- Aug 2022
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of roflumilast in type 2 diabetes mellitus (T2DM) and diabetic neuropathy (2 arms), sponsored by Tanta University. Primary endpoints: Change in fasting blood glucose at 3 months, Change in plasma insulin level at 3 months and 3 more. Started Aug 2022; status: completed.
02
Drugs
roflumilast
03
Conditions
type 2 diabetes mellitus (T2DM)diabetic neuropathy
Beyond the preview
Go deeper on NCT05369793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05369793.